Kathy Bergsteinsson

Chief Financial Officer @ Affini-T Therapeutics arrow icon

About Kathy Bergsteinsson

Kathy Bergsteinsson is the Chief Financial Officer with a strong background in finance, having previously led over 70 IPOs and managed more than $100 billion in equity financing at Morgan Stanley.

Known information

Kathy Bergsteinsson serves as the Chief Financial Officer, bringing a robust expertise in financial management and strategic transactions. She began her career in the mergers and acquisitions department at Morgan Stanley, where she advised on transactions totaling over $100 billion. Kathy later transitioned to become the Managing Director and Head of Healthcare Equity Capital Markets at the same institution. In this role, she was instrumental in raising over $100 billion in equity financing for clients through more than 70 initial public offerings and 175 follow-on common stock offerings, convertible debt offerings, and private placement transactions. Kathy holds a Bachelor of Science degree in industrial engineering from Stanford University and a Master of Business Administration from The Wharton School at the University of Pennsylvania.

About Affini-T Therapeutics

Affini-T Therapeutics, based in Watertown, MA, develops TCR-based immunotherapies for solid tumors, focusing on oncogenic mutations such as KRAS and p53.

report flag Report inaccurate information

People similar to Kathy Bergsteinsson

Dirk Nagorsen is the Chief Medical Officer who previously worked at Amgen.

Thaminda Ramanayake is the Chief Business Officer with a Master of Science and a Master of Business Administration degree.

Kathy Yi

Chief Operating Officer @ Affini-T Therapeutics

Kathy Yi serves as the Chief Operating Officer.

Unlock exclusive insights

Sign up to reveal more information.

loader Sign up for free